Across TCGA pan-cancer cohorts, RAB33A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB33A data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RAB33A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB33A expression acts as an unfavorable survival marker.
KIRP, LIHC, and UCEC are the cancer types where RAB33A Mutation most reproducibly stratifies survival.